ZFIN Image: Mohanty et al., 2022, Fig. 7

Image

Figure Caption

Fig. 7

Evaluation of combinatorial anti-tumor effect of low dose of cisplatin, 5FU and lestaurtinb in TPF resistant patient derived cells (PDC2).

A, B PDC2 cells were treated with indicated concentrations of cisplatin, 5FU and lestaurtinib for 48 h and cell viability was measured by MTT assay (n = 3 and, ****P < 0.0001 by 2-way ANOVA). C PDC2 cells were treated with indicated concentrations of cisplatin, 5FU and lestaurtinib for 48 h after which cell death was determined by annexin V/7AAD assay using flow cytometer. Bar diagrams indicate the percentage of cell death (early and late apoptotic) with respective treated groups (Mean ± SEM, n = 3 by Two-way ANOVA, ****P < 0.0001). D PDC2 cells were treated with indicated concentrations of cisplatin, 5FU and lestaurtinib for 48 h and immunoblotting (n = 3) was performed with indicated antibodies. E PDC2 cells were treated with indicated concentrations of cisplatin, 5FU, lestaurtinib for 12 days and colony forming assays were performed as described in method section. Left panel: Bar diagram indicate the relative colony number (n = 3 and, ****P < 0.0001 by 2-way ANOVA). Right panel: representative photographs of colony forming assay in each group.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene